Search the Newsreel

Mallcom (India) Share Price Target 2027 to 2030: Analyst Outlook

Cibus (CBUS) Q2 2026 Earnings Call: Rice Launch Moves to 2028 as Costs Decline

Ascentis Wealth Management LLC Raises Holdings in GE Vernova Inc. $GEV

Ascentis Wealth Management LLC significantly increased its stake in GE Vernova Inc. by 60,776.3% in the second quarter, now owning 138,798 shares valued at over $163 million. The article also highlights key news impacting GE Vernova, including strong Q2 revenue growth, AI and data-center …

Share Price Today - Allcargo Global Ltd. Stock Price Live NSE/BSE

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

Celcuity Inc. announced its Q2 2026 financial results, highlighted by the FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- PIK3CA Wild-Type breast cancer and its inclusion in NCCN guidelines. The company plans a commercial launch for REVTORPYK in late Q3 2026 and intends to submit …

Zentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/share

Zentalis Pharmaceuticals (ZNTL [https://seekingalpha.com/symbol/ZNTL]) announced the pricing of an underwritten public offering [https://seekingalpha.com/pr/20619418-zentalis-pharmaceuticals-announces-pricing-of-underwritten-public-offering] of 23M shares of its common stock at a public offering price of $3.50 per share. Gross proceeds from the offering are expected to be approximately $80.5M before deducting underwriting discounts, …

Zentalis Pharma Prices $80.5 Mln Offering Of Shares At $3.50 Per Share; Stock Down

(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage oncology company, priced a public offering of 23 million shares at $3.50 per share. The total gross proceeds from the offering are expected to be $80.5 million, and the company plans to use the net proceeds …

Cibus Inc (CBUS) (Q2 2026) Earnings Call Highlights: Strategic P

Key Points Interested in Cibus, Inc.? Here are five stocks we like better. Revenue increased 35% year over year to $2.7 million for the first six months of 2026, while second-quarter net loss narrowed to $22.1 million from $26.6 million. Cost-cutting reduced combined R&D …

Kaplan Fox is Investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) on Behalf of Investors

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. following a whistleblower complaint. The complaint alleges accounting irregularities that artificially inflated the company's financial results, specifically Adjusted EBITDA. This news led to a significant drop in Alignment Healthcare's stock …

Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50

Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) has announced the pricing of an underwritten public offering of 23 million shares of common stock at $3.50 per share, aiming to raise approximately $80.5 million in gross proceeds. The offering is expected to close on August 17, 2026, with …

ALHC5941479 Bond Profile — Key Metrics

This article provides key metrics for the ALHC5941479 bond issued by Alignment Healthcare, Inc. The bond has a 4.25% coupon rate and matures on November 15, 2029. Alignment Healthcare is described as a holding company that offers customized healthcare solutions, primarily Medicare Advantage plans, …

5 Insightful Analyst Questions From Dynatrace’s Q2 Earnings Call

5 Insightful Analyst Questions From Dynatrace's Q2 Earnings Call Dynatrace's second quarter was marked by strong revenue growth and a positive market response, as the company surpassed Wall Street's revenue expectations and posted robust demand for its cloud observability platform. Management attributed this momentum …

Cibus updates Latin America rice launch to 2028 while outlining $20M-$40M biofragrance revenue opportunity

Earnings Call Insights: Cibus, Inc. (CBUS) Q2 2026 MANAGEMENT VIEW * CEO Craig Wichner framed his priorities around scaling revenue and tighter spending control, saying, "I accepted the job of CEO because I believe we can generate revenue at scale. That is my mission." …

Cibus (NASDAQ:CBUS) Releases Earnings Results

Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis

Barclays PLC has filed an amended Schedule 13G, disclosing a 3.17% beneficial ownership stake in Zentalis Pharmaceuticals Inc. (ZNTL), totaling 2,263,328 shares as of June 30, 2026. This filing indicates that Barclays now holds 5 percent or less of the class. The ownership includes …

Sprouts Farmers Market Inc (SFM) Stock Down 3.9% -- Now Undervalued?

Sprouts Farmers Market Inc (SFM) shares dropped 3.9% to $82.68, placing it below its GF Value™ of $96.25, suggesting it is undervalued by 14.1%. Despite a strong GF Score™ of 93/100, indicating good overall performance, significant insider selling of $6.7M over the last three …

Kaplan Fox Urges Alignment Healthcare, Inc. (NASDAQ: ALHC) Investors to Contact the Firm Regarding a Securities Investigation

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. (NASDAQ: ALHC) following allegations of "accounting irregularities" that "artificially inflated" the company's reported financial results. A whistleblower complaint claims that operating expenses were systematically misclassified as capital expenditures. This news …

Celcuity (CELC) Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity

Celcuity (CELC) has received FDA approval for REVTORPYK for certain metastatic breast cancer patients and its inclusion in NCCN guidelines. Despite this positive news, the stock has experienced a significant pullback, falling 22% over 30 days and 37.1% over 90 days. Analysts currently value …

Celcuity Q2 Earnings Call Highlights

Key Points Interested in Celcuity, Inc.? Here are five stocks we like better. REVTORPYK launch remains on track: Celcuity expects commercial shipments of its FDA-approved gedatolisib therapy for certain advanced breast cancer patients to begin in late Q3 2026. The treatment has a $30,000 …

Is Alignment Healthcare (ALHC) Undervalued Following Whistleblower Claims And Accounting Investigations?

CELCUITY ($CELC) Releases Q2 2026 Earnings

CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch

Celcuity Inc. (CELC) received FDA approval for REVTORPYK for HR-positive, HER2-negative advanced breast cancer, supported by strong trial data and NCCN guideline inclusion. Despite a Q2 net loss of $78.9M, the company has a robust cash position due to a $575M convertible note, setting …

Earnings call transcript: Celcuity Q2 2026 loss widens as launch nears

Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates

Celcuity Inc. (NASDAQ: CELC) deepens loss as it raises $575M in converts

Celcuity beats second quarter loss estimates

Celcuity Inc. reported an adjusted loss of $1.07 per share for the second quarter of 2026, surpassing analyst estimates. The company's shares rose 1% after the announcement, driven by the recent FDA approval of its breast cancer treatment, REVTORPYK. Celcuity expects to begin shipments …

Is BellRing Brands (BRBR) Undervalued After Better Than Expected Q3 Results?

BellRing Brands (BRBR) reported better-than-expected Q3 2026 results and updated guidance, including plans for double-digit price increases on Premier products in fiscal 2027. Despite a significant share price drop over the past year, Simply Wall St suggests the stock is 23.6% undervalued compared to …

Cibus (CBUS) narrows Q2 2026 loss as cash burn falls and regulatory tailwinds build

Celcuity GAAP EPS of -$1.44 misses by $0.28

* Celcuity press release [https://seekingalpha.com/pr/20619145-celcuity-inc-reports-release-of-second-quarter-2026-financial-results-and-provides-corporate] (CELC [https://seekingalpha.com/symbol/CELC]): Q2 GAAP EPS of -$1.44 misses by $0.28. * Total operating expenses were $66.1 million for the second quarter of 2026, compared to $44.0 million for the prior year period. Research and development (“R&D”) expenses were $31.1 …

electroCore (ECOR) investors report 9.9% stake and 1.55M-share warrant position

A group of investors, including Charles Steve Theofilos, M.D., Kathryn Theofilos, and Happy Holstein Management, LLC, have disclosed a 9.9% beneficial ownership stake in electroCore (ECOR). This stake comprises 938,523 shares of common stock, including 375,000 shares exercisable from warrants. Happy Holstein Management, LLC …

Earnings Flash (CELC) Celcuity Inc. Posts Q2 Adjusted Loss $1.07 per Share, vs. FactSet Est of $-1.12

Celcuity Inc. (CELC) reported a Q2 adjusted loss of $1.07 per share, which was better than the FactSet estimate of $-1.12 per share. The article, published on August 13, 2026, also noted that Celcuity's Q2 adjusted loss widened. This news follows several recent developments …

Cibus (CBUS) cuts costs but warns on going concern amid Q2 2026 loss

Cibus (CBUS) reported a Q2 2026 net loss of $22.1 million and a year-to-date net loss of $43.4 million, along with a warning about its ability to continue as a going concern due to recurring losses and limited cash. Despite modest revenue growth and …

MDB Capital Holdings (MDBH) records $16.1M H1 2026 loss and $33.1M eXoZymes stake

Boise Cascade (BCC) sees Wellington group report 5.19% beneficial stake

Wellington Management Group LLP, along with its affiliated entities, has reported a beneficial ownership of 5.19% in Boise Cascade Company (BCC), totaling 1,824,952 shares of common stock as of June 30, 2026. The group exercises shared voting power over 1,627,277 shares and shared dispositive …

EagleRock Land (NYSE: EROK) doubles revenue after IPO but records H1 2026 loss

EagleRock Land (NYSE: EROK) reported a significant increase in revenue to $64.6 million for the first half of 2026, more than double the previous year, following its May 2026 IPO and recent acquisitions. Despite this revenue growth, the company recorded a net loss of …

Zentalis Pharmaceuticals stock falls on public offering news

Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) shares dropped 6.5% after announcing an underwritten public stock offering, which will include common stock and pre-funded warrants. The company plans to use the proceeds to fund clinical trials, preclinical studies, regulatory filings, and manufacturing for its oncology programs, particularly …